Member Info for stevej

Application number GB2005114.0
Sareum limited
Crystalline Forms of a Pharmaceutical compound
Date lodged 7th April 2020

Don’t you mean 36p would give us market cap of £1 B……… frightening from the days of 0.0025p

Hi Stoney,
Agree (13 years for me) but think it might takes a few weeks ( mid July for me) before we see results but never seen the bod so relaxed and even driving SP up with recent placing. It’s taken a bit longer than I’m sure we anticipated when we invested but the rewards now are mind blowing for us all. Just need the confirmation of trial results and then the news to get behind it and I honestly do know where we can get too in SP but the 10p is now seriously under estimated but was agreed 7-8 years ago ??. Good luck everyone, not posting much over the last few years due to work commitments but look in daily at the great posts from some truly well researched people

SDC-1801 – Autoimmune diseases & Covid-19
• Good efficacy in RA and Psoriasis disease models
• Initial toxicology studies completed
• Aiming to complete tox studies and file an exploratory CTA in H2 2021*
• Projected Phase 1 start early 2022*
• Manufacturing route completed

Last line says it all!

Thinking we might all need to take the week off for the 10p party ??, been over 10 years in the making ??

RNS was dated 26th March

Wording suggests we should of already received the payment if due within 9 months or can cancel contract which would suggest Chinese wouldn’t risk not paying on time if they have got it to work..... RNS due.....?

Under the terms of the Agreement, the Licensee will fund all future development activities in relation to the Compounds and has been granted sole rights to market any resulting products worldwide.

Sareum will receive an initial upfront payment of approximately £50,000. A further payment of approximately £0.9 million will be payable to Sareum if certain milestones related to the oral bioavailability of the Compounds are achieved within nine months from the date of the Agreement (the "Development Payment").

Sareum will assign certain patents in respect of the Compounds to the Licensee upon receipt of the Development Payment. The Agreement may be terminated with immediate effect if Sareum does not receive the Development Payment within nine months of the date of the Agreement.

Portfolio update June 19

Sareum's recent activities have focused on toxicology studies designed to gain insight to the maximum-tolerated doses (MTD) of SDC-1801 and SDC-1802 in rodents. SDC-1801 is further advanced and currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies; an MTD has yet to be reached.

Hi Hopkirk, I hope you are well. I agree and hopefully he has now registered for a grant!

"In conclusion, as insight is gained into the clinical phenotypes associated with COVID-19, we propose JAK and IL-1 inhibitors as therapeutic targets warranting rapid investigation" thelancet.com/journals/lanre…
Sareum $SAR.L #TYK2 #AIM #biotech #Covid-19

Presentation on Sareum website.....

Diseases such as Covid-19, SARS, MERS, influenza etc. can be fatal due to a “cytokine storm” overreaction of the immune system
• Key cytokines elevated in Covid-19 ICU patients are reported to include:
• IL-2, IL-7, IL-10, G-CSF – all signal via JAK-family kinases
• Clinical trials of JAK-family inhibitors ruxolitinib, tofacitinib, baricitinib in Covid-19 patients are in progress or planned
• Secondary bacterial infections induce IL-1ß and GM-CSF
• GM-CSF reported to improve outcome in patients with pneumonia-associated ARDS
• IL-1ß - GM-CSF pathway blocked by virally-induced IFNa and IFN?
• TYK2/JAK1 inhibition blocks IFNa/? signalling and thus restores GM-CSF levels
• GM-CSF signals via JAK2
• Suggests a TYK2/JAK1 inhibitor that does not inhibit JAK2 to be optimally beneficial
• Sareum’s SDC-1801/2 inhibit TYK2 and JAK1, but not JAK2

Should be interesting today....

The presentation will provide an update of Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively. Dr Mitchell will also highlight the emerging potential of this mechanism to modulate the severe inflammatory responses and respiratory symptoms arising from coronavirus and other viral infections.

Reminds me of the fake email circulating in Feb 2011 where GSK we’re going to offer 22p ????

Hi Del77, still here mate in the background from 2008. Still hold a few million as believe in the company, but not really had the time to post. I do appreciate the posts as some really knowledgeable posters with good research. Still awaiting the 10p party

I can’t see it being this year now, but fingers crossed. Have a great Christmas everyone

PYC consolidated their shares from memory!

Programs continue to progress which is good news but updates getting worse by Tim and John, not impressed!

Have I missed something about us being in Phase 2 as I thought phase one was listed to be finished April 19? Appreciate the link in phase 2

Thanks Del77, appreciate your post. I think I�m in my ninth year here and even more confident than ever and long overdue. Work keeping me from posting much over the last few years but still have the faith and leave it to many knowledgeable posters to keep everyone informed. Hope you get your price over the coming months and good luck

To me they have some news pending on one of the other programs that they want to include in the update post half year and will only be good for us all.

Worth looking at today as share price 2.13 but placing at 7p!!!!............surely he could of bought the company for a bit more.......................should see a good rise today but don't get caught out buying too high.....GL